rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TRDA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
      Nov 5Yahoo FinanceTRDA
      Entrada Therapeutics names Linea Aspesi as chief people officer
      Oct 21Investing.comTRDA
      Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer

      A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of growth Linea Aspesi Linea Aspesi BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. “Linea has a proven track record of scaling organizations and developing high-performing teams from discovery through commercial stages,” said Dipal Doshi, Chief Ex

      Oct 21Yahoo FinanceTRDA
      What's Going On With Entrada Therapeutics Stock Wednesday? - Entrada Therapeutics (NASDAQ:TRDA)

      TRDA stock fell over 15% after Entrada Therapeutics announced initial Phase 1/2 ELEVATE-45-201 study results for ENTR-601-45.

      Oct 14BenzingaTRDA
      What's Going On With Entrada Therapeutics Stock Wednesday?
      Oct 14Yahoo FinanceTRDA
      Entrada receives clearance to test highest dose in DMD trial
      Oct 14Investing.comTRDA
      Entrada Says First Cohort of ENTR-601-45 Phase 1/2 Trial Shows 'Positive' Safety Results in Duchenne Muscular Dystrophy
      Oct 14Yahoo FinanceTRDA
      Entrada reports phase 1/2 trial data for DMD therapy candidate
      Oct 14Investing.comTRDA
      Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

      -- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate exposure data -- -- In line with expectations, the secondary objectives demonstrated a 0.10% mean increase in dystrophin production versus baseline in treated participants at the initial dose of 5 mg/kg -- -- Company expects a significant increase in dystrophin production and function

      Oct 14Yahoo FinanceTRDA
      Entrada Stock: Weak Dystrophin Data May Be Creating A Buying Opportunity

      Entrada Therapeutics (ENTR) Buy call: $8.50 fair value (~52% upside). Valuation is anchored by risk-adjusted pipeline estimates. See more details here.

      Oct 10Seeking AlphaTRDA
      Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead
      Sep 9Investing.comTRDA
      Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock
      Sep 9Investing.comTRDA
      Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares
      Sep 9Investing.comTRDA
      Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares
      Sep 4Investing.comTRDA
      Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics
      Sep 4Investing.comTRDA
      Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock
      Aug 31Investing.comTRDA
      Mpm Bioventures 2018 sells $615,777 in Entrada Therapeutics stock
      Aug 31Investing.comTRDA
      Mpm Bioventures sells $461,545 in Entrada Therapeutics stock
      Aug 27Investing.comTRDA
      Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock
      Aug 27Investing.comTRDA

      This is the newest page. Registered accounts read further back.